The Clinical Question Behind STEP 8
A 52-year-old patient on liraglutide 3.0 mg (Saxenda) for ten months has lost 5% of body weight and plateaued. The prescribing clinician has two GLP-1 receptor agonists on formulary and no direct comparative trial to lean on — only separate studies run years apart, in different populations, under different protocols. That gap is exactly what the STEP 8 trial was built to close. Registered as NCT04813107 and published by Rubino and colleagues in JAMA in 2022, STEP 8 was the first adequately powered randomized trial to compare semaglutide vs liraglutide head-to-head, in the same population, under the same conditions, over the same 68-week window.
Before STEP 8, clinicians inferred relative efficacy by placing the SCALE trial (liraglutide, NCT01272219) next to STEP 1 (semaglutide, NCT03548935) and eyeballing the difference in percent weight change. That method ignores differences in enrollment criteria, trial era, and placebo response, all of which distort apparent effect size. STEP 8 removed the guesswork by randomizing participants to one of two active drugs or placebo within a single trial — the only design that supports a direct superiority claim rather than a cross-trial impression.
STEP 8 Trial Design and Patient Population
STEP 8 enrolled 338 adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity, none of whom had type 2 diabetes. Participants were randomized 2:2:1 to semaglutide 2.4 mg once weekly, liraglutide 3.0 mg once daily, or placebo, for 68 weeks total. The trial used a double-dummy design — every participant received both a weekly injection and a daily injection, with one of the two being an inactive placebo matched to the active comparator's schedule — specifically to prevent unblinding based on injection frequency alone.
Dose titration followed each drug's standard pivotal-trial protocol rather than a harmonized schedule, which matters for interpreting the tolerability data later in the trial. Semaglutide was titrated upward over 16 weeks to the 2.4 mg maintenance dose, following the same stepwise schedule detailed in prior work on semaglutide dose titration protocols from pivotal trials. Liraglutide was titrated over roughly 4 to 5 weeks to its 3.0 mg maintenance dose, consistent with its FDA labeling. Mean baseline body weight across arms was approximately 105 kg, with a mean BMI near 38 kg/m², and the population was roughly 73% female with a mean age in the mid-to-late 40s — broadly representative of the populations enrolled in the SCALE and STEP 1 trials, which is part of why the head-to-head design carries more weight than cross-trial inference.
Primary Endpoint: Percent Weight Change at Week 68
The primary endpoint was percent change in body weight from baseline to week 68. Semaglutide produced a mean reduction of -15.8%, liraglutide produced -6.4%, and placebo produced -1.9%. The estimated treatment difference between semaglutide and liraglutide was -9.4 percentage points (95% CI, -12.0 to -6.8; P<0.001), establishing statistical superiority for semaglutide on the trial's primary measure.
That 9.4-point gap is the number that matters most in a clinical decision, because it is not a cross-trial artifact — it was measured in the same 338 people under the same monitoring schedule. For a patient starting at 105 kg, the difference between a 15.8% and a 6.4% reduction translates to roughly 16.6 kg versus 6.7 kg lost over 68 weeks, a gap of about 10 kg that has downstream implications for blood pressure, joint load, and glycemic trajectory even in a population without diagnosed type 2 diabetes at baseline.
It is worth being precise about what this endpoint does and does not establish. STEP 8 demonstrates superiority on body weight percentage change specifically in a non-diabetic population over 68 weeks; it does not, by itself, establish differences in cardiovascular outcomes, mortality, or long-term weight maintenance after drug discontinuation. Those questions are addressed elsewhere, including in long-term follow-up data from the STEP 4 discontinuation and weight regain analysis.
Secondary Endpoints: Responder Rates and Clinical Thresholds
Trial primary endpoints report averages, but clinicians make decisions based on how many patients cross meaningful thresholds. STEP 8's secondary endpoints quantify that distribution. Among semaglutide-treated participants, 70.9% achieved at least 10% weight loss, compared with 25.6% on liraglutide and 9.6% on placebo — a nearly three-fold difference in the proportion reaching a threshold commonly used as a marker of clinically meaningful metabolic benefit.
At the higher threshold of 15% weight loss, the gap widens further: more than half of semaglutide-treated participants reached that mark, compared with roughly one in eight on liraglutide. These responder curves matter more in a shared decision-making conversation than the mean percentage alone, because a patient wants to know their individual odds of reaching a specific target, not just the group average.
- ≥5% weight loss: achieved by the large majority of semaglutide-treated participants, a minority on placebo
- ≥10% weight loss: 70.9% semaglutide vs 25.6% liraglutide vs 9.6% placebo
- ≥15% weight loss: achieved by roughly half of semaglutide-treated participants, a small fraction of the liraglutide group
Secondary measures of waist circumference, systolic blood pressure, and fasting lipid markers also favored semaglutide numerically, though STEP 8 was not statistically powered to make formal superiority claims on those endpoints individually, and the trial authors note them as supportive rather than definitive findings.
Gastrointestinal Tolerability and Discontinuation Rates
Overall rates of gastrointestinal adverse events were close between the two active arms — 84.1% for semaglutide and 82.7% for liraglutide — both substantially higher than the 33.3% reported on placebo. Nausea, diarrhea, constipation, and vomiting were the most frequently reported events in both groups, and the trial characterized most as mild to moderate in severity, consistent with findings described in the broader mechanistic review of GLP-1 receptor agonists and gastric emptying as the mechanism behind nausea.
The more clinically actionable finding is discontinuation due to adverse events, which diverged clearly between the two drugs: a meaningfully lower proportion of semaglutide-treated participants stopped the drug because of side effects compared with the liraglutide group. In practical terms, similar symptom incidence did not translate into similar dropout — participants on liraglutide were more likely to find the symptom burden severe enough, or persistent enough, to stop treatment altogether.
For a clinic managing a panel of patients on either drug, this distinction changes how tolerability conversations should be framed at the first follow-up visit. Expecting some gastrointestinal symptoms on either drug is appropriate; what warrants closer monitoring is whether those symptoms are trending toward intolerable rather than simply present, since STEP 8 suggests that trajectory differs meaningfully between the two agents even when initial symptom rates look alike.
Mechanism: Why Once-Weekly Dosing Changes the Efficacy Profile
The efficacy gap in STEP 8 is not arbitrary — it tracks with a clear pharmacokinetic difference between the two molecules. Semaglutide's elimination half-life is approximately 165 hours, or about seven days, driven by a fatty diacid side chain that promotes site-2 albumin binding and resistance to DPP-4 degradation via an aminoisobutyric acid substitution at position 8. Liraglutide, acylated with a shorter C16 fatty acid side chain, has an elimination half-life of approximately 13 hours.
That roughly twelve-fold difference in half-life means semaglutide maintains far steadier plasma concentrations and more consistent GLP-1 receptor engagement across a dosing interval, even though both drugs are injected subcutaneously and both bind albumin at greater than 98% to resist rapid renal clearance. Liraglutide's shorter half-life produces more peak-and-trough variability within each 24-hour cycle, which plausibly contributes to both its lower sustained efficacy and its distinct tolerability trajectory. A fuller discussion of receptor binding kinetics and downstream signaling appears in the dedicated review of GLP-1 receptor mechanism of action and why pharmacology predicts tolerability.
This mechanistic difference also explains why the two drugs cannot be dosed interchangeably on a simple mg-for-mg basis, and why clinicians transitioning a patient between agents rely on established titration schedules rather than a direct dose conversion.
What Changed in Clinical Practice After STEP 8
Before 2022, treatment guidelines and payer policies often listed semaglutide and liraglutide as roughly interchangeable GLP-1 options for obesity management, differentiated mainly by injection frequency and cost. STEP 8 gave clinical guidance bodies a data-backed basis to differentiate the two on expected magnitude of benefit, not just convenience. Several professional obesity-medicine guidelines updated language following STEP 8 and the broader STEP program to reflect semaglutide's larger expected effect size when access and cost allow for either choice.
The trial also reframed how comparative obesity-drug claims are expected to be substantiated going forward. Competing analyses of newer agents, including comparisons between tirzepatide and semaglutide in the SURMOUNT-5 head-to-head weight loss trial data, now follow the same direct-randomization standard STEP 8 established rather than relying on cross-trial percentage comparisons.
For a prescribing practice weighing formulary decisions, the practical shift has been toward defaulting to semaglutide for treatment-naive obesity patients when insurance coverage and supply allow, reserving liraglutide for specific circumstances rather than treating it as a coin-flip alternative. That shift is a direct consequence of having randomized, within-trial evidence rather than an assumption carried over from separate trial populations.
Where Liraglutide Still Has a Defined Role
STEP 8's result does not make liraglutide obsolete in every scenario. Liraglutide 3.0 mg remains FDA-approved for chronic weight management and carries a longer track record, with the original SCALE program dating to 2014, giving clinicians more years of accumulated real-world safety data to draw on for complex cases.
Daily dosing, often framed as a drawback, offers one practical advantage: faster titration adjustment. If a patient develops intolerable nausea on a given liraglutide dose, the next lower dose is reached within a day; with semaglutide's weekly schedule, adjusting exposure takes a full week to manifest at a given dose. For patients with a history of severe GLP-1-related gastrointestinal intolerance who want the option to step back quickly, that daily granularity has clinical utility.
Liraglutide also functions as a practical fallback during periods of semaglutide or tirzepatide supply constraints, and it is sometimes the lower-cost option on specific insurance formularies. None of these are efficacy arguments — STEP 8's data on magnitude of weight loss stands — but they are legitimate access and tolerability-management reasons a clinician might still reach for liraglutide in a specific case rather than treating semaglutide as the default in every scenario.
Monitoring, Contraindications, and Shared Decision-Making
Both drugs carry the same boxed warning for thyroid C-cell tumors observed in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both require caution in patients with a history of pancreatitis, and both warrant baseline and periodic monitoring of renal function given the risk of dehydration from persistent vomiting or diarrhea during titration.
Shared decision-making conversations should address expected timeline, not just expected magnitude. A patient choosing semaglutide based on STEP 8's superior average result should understand that the full 68-week trajectory — not an early plateau — is what the trial measured, and that premature discontinuation changes the expected outcome substantially, a pattern explored further in the STEP 4 long-term follow-up findings on discontinuation and weight regain. Clinicians should also set expectations around lean mass monitoring during rapid weight loss on either agent, a consideration detailed in the review of preserving lean muscle mass during GLP-1-driven weight loss.
Routine visit intervals during titration — typically every 4 weeks for dose escalation decisions — should include a structured symptom check rather than a general tolerability question, since STEP 8's data shows that similar reported symptom rates can still produce different discontinuation trajectories depending on how those symptoms are managed early.
Bottom Line for Clinical Decision-Making
STEP 8 answers a question that cross-trial comparison could only approximate: when semaglutide and liraglutide are tested in the same patients under the same conditions, semaglutide produces substantially greater weight loss and fewer treatment-ending side effects, despite similar initial symptom burden. The estimated treatment difference of -9.4 percentage points at week 68, with a 95% CI excluding zero and a P-value below 0.001, is not a marginal or borderline finding.
The concrete action step for a clinician evaluating a treatment-naive obesity patient without a strong cost or access constraint is to weigh semaglutide as the evidence-preferred starting point based on STEP 8's superiority data, while documenting the specific reason — cost, supply, or tolerability history — whenever liraglutide is selected instead. For a patient already stable and responding on liraglutide, STEP 8 is not, by itself, a reason to switch; it is a reason to re-evaluate specifically when response has plateaued or adverse events have become a barrier to continuation.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.